These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32847379)
1. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction. Palmer S; Tillman F; Sharma P; Auten J; Owen K; Clark SM; Morgan KP Ann Pharmacother; 2021 Mar; 55(3):303-310. PubMed ID: 32847379 [TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851 [TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Major PP; Coleman RE Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861 [TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Brufsky AM; Sereika SM; Mathew A; Tomifumi O; Singh V; Rosenzweig M Breast J; 2013; 19(5):504-11. PubMed ID: 23800050 [TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy. Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992 [TBL] [Abstract][Full Text] [Related]
6. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Major P Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736 [TBL] [Abstract][Full Text] [Related]
7. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092 [TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis]. Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients. Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125 [TBL] [Abstract][Full Text] [Related]
10. Effect of zoledronic acid and pamidronate on renal function. Koss K; Kocek M; King T; Hornung M J Oncol Pharm Pract; 2024 Sep; ():10781552241284635. PubMed ID: 39285742 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in multiple myeloma: a network meta-analysis. Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688 [TBL] [Abstract][Full Text] [Related]
12. Safety of pamidronate in patients with renal failure and hypercalcemia. Machado CE; Flombaum CD Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358 [TBL] [Abstract][Full Text] [Related]
13. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Guarneri V; Donati S; Nicolini M; Giovannelli S; D'Amico R; Conte PF Oncologist; 2005; 10(10):842-8. PubMed ID: 16314295 [TBL] [Abstract][Full Text] [Related]
14. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy. Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289 [TBL] [Abstract][Full Text] [Related]
16. Use of Pamidronate for Hypercalcemia of Malignancy in Renal Dysfunction. Norman SJ; Reeves DJ; Saum LM J Pharm Pract; 2021 Aug; 34(4):553-557. PubMed ID: 31648595 [TBL] [Abstract][Full Text] [Related]
17. Current management strategies for hypercalcemia. Pecherstorfer M; Brenner K; Zojer N Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562 [TBL] [Abstract][Full Text] [Related]
18. Treatment of hypercalcemia of malignancy with bisphosphonates. Berenson JR Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690 [TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid: a new parenteral bisphosphonate. Li EC; Davis LE Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298 [TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]